Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Gemcitabine combination chemotherapy of ovarian cancer.
David G. Mutch
Division of Gynecologic Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
22
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Gemcitabine combination chemotherapy of ovarian cancer.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Gemcitabine
100%
Ovarian Cancer
100%
Combination Chemotherapy
100%
First-line Therapy
33%
Platinum Compounds
33%
Response Rate
22%
Clinical Trials
22%
Paclitaxel
22%
Cytotoxic Agents
22%
Newly Diagnosed Patients
11%
Carboplatin
11%
Salvage Therapy
11%
Previously Untreated Patients
11%
Mechanism of Action
11%
Prior Treatment
11%
Cisplatin
11%
Medicine and Dentistry
Ovarian Cancer
100%
Combination Chemotherapy
100%
Gemcitabine
100%
Platinum Derivative
33%
Clinical Trial
22%
Paclitaxel
22%
Chemotherapy
22%
Cytotoxic Agent
22%
Carboplatin
11%
Cisplatin
11%
Salvage Therapy
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Ovary Cancer
100%
Gemcitabine
100%
Platinum Derivative
33%
Clinical Trial
22%
Paclitaxel
22%
Cytotoxic Agent
22%
Cisplatin
11%
Carboplatin
11%
Diseases
11%